The dramatic therapeutic effects of neoadjuvant chemotherapy (NCT) in the breast and documented nodal metastases has been demonstrated for several decades.
1-3 During this time, our understanding of the biology of breast cancer, response to NCT, and integration of these findings into clinical practice has changed the surgical management of breast cancer. A pathologic complete response (pCR) in the breast (hereinafter referred to as breast pCR) to NCT, defined as no residual invasive or in situ disease, is known to confer disease-free and overall survival benefits.
1,4,5 The variability of breast pCR rates among different subtypes of breast cancer has been extensively studied. Patients with
HER2 (now
ERBB2)-positive (
HER2+)/triple-negative (TN) subtypes have a higher incidence of breast pCR than patients with luminal type A or B.
6,7 Tumor size is also an independent predictor of pCR, with T1 and T2 tumors having higher rates of pCR than T3 or T4 tumors. The implementation of dual systemic agent therapy for breast cancer targeting human epidermal growth factor receptor 2 is now routinely incorporated for patients with
HER2+ tumors.
8 This process has led to increased rates of breast pCR among patients with the
HER2+ subtype.
9